Drugs / Sacubitril / Valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03893435 | Dec 2018 → Jul 2022 | acute myocardial infarction | The Young Investigator Group of Cardiovascular Research | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-07-07 | Novartis Pharmaceuticals | Regulatory Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook novartis.com ↗
Novartis today announced that the U.S. District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-07-07 | Novartis Pharmaceuticals | Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril / Valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03893435 ↗ |
| Known as | Entresto | “Sacubitril / Valsartan Oral Tablet [Entresto]” NCT03893435 ↗ |
| Route | Oral | “97 mg/103 mg PO BID” NCT03893435 ↗ |